Coronavirus / COVID

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Here’s where you should sit on the bus to avoid COVID-19 droplets.

Less than 3 weeks after it was first reported, Omicron becomes the dominant COVID-19 variant in the US.

In the age of COVID-19, providers caring for patients with emerging diseases do not rely entirely on clinical guidelines, but also consult online resources that are updated more frequently. This needed integration helps providers adapt to the best-available evidence into bedside care when guidance is lacking.

Respiratory syncytial virus (RSV) cases decreased due to COVID-19 precautions. Investigators estimated the rate and timing of RSV resurgence over the next few years.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Will this winter bring the feared twindemic of SARS-CoV-2 and influenza, or will another common infection reemerge?

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

A study of patients hospitalized with COVID-19 pneumonia found namilumab, but not infliximab, significantly reduced inflammation and CRP concentration.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

Children in the United States will be able to avoid potentially millions of hours of at-home quarantining under a testing program unveiled by the CDC today.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A clinical trial of 8 sub-Saharan African countries will be the first to study the efficacy of mRNA COVID-19 vaccination in people living with HIV.

Patients with severe COVID-19 who received high-flow oxygen therapy were less likely to need mechanical ventilation and had a shorter time to clinical recovery, investigators in Colombia found.

The company believes the pill should work against the Omicron variant.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Health officials in Mississippi reported a sharp increase in COVID-19-associated deaths among pregnant women during after the Delta variant became predominant.

The FDA granted an Emergency Use Authorization to Evusheld, AstraZeneca’s long-acting monoclonal antibodies for COVID-19 prevention in high-risk individuals.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

New research reveals that women who test positive for COVID-19 at the time they give birth pass along antibodies in breast milk, protecting their newborns from infection

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

High-titer convalescent plasma administered to high-risk outpatients within a week of symptom onset didn’t prevent disease progression, according to a new study.